Is pancreatitis associated with meglumine antimoniate treatment for canine leishmaniosis? A multicentric prospective study
Viñeta, Clàudia (Universitat Autònoma de Barcelona. Hospital Clínic Veterinari)
Castro, Jorge (AniCura Valencia Sur. Hospital Veterinario)
Lopez, Maria Cristina (Universitat Autònoma de Barcelona. Hospital Clínic Veterinari)
Frau, Maria (Universitat Autònoma de Barcelona. Hospital Clínic Veterinari)
Costas, Antón (AniCura Valencia Sur. Hospital Veterinario)
Arenas Bermejo, Carolina (AniCura Valencia Sur. Hospital Veterinario)
Roura, Xavier (Universitat Autònoma de Barcelona. Hospital Clínic Veterinari)

Fecha:	2024
Resumen:	Meglumine antimoniate is used to treat canine leishmaniosis. In humans, it has been associated with pancreatitis. Although a few case reports have described acute pancreatitis secondary to antimonial treatment in dogs, some studies have concluded that pancreatitis is not an adverse effect of this medication. The objective was to evaluate whether treatment with meglumine antimoniate could induce pancreatitis in dogs with leishmaniosis, on the basis of clinical signs, canine serum specific quantitative pancreatic lipase immunoreactivity (cPLI) concentration, and ultrasonographic abnormalities. A prospective, observational, longitudinal, and multicentric study was conducted from April 2021 through February 2023. A total of 33 dogs with leishmaniosis were included and classified into LeishVet clinical stages; 13 (39. 4%) were included in stage II, 11 (33. 3%) in stage III, and 9 in stage IV (27. 3%). and 14 (42. 4%) developed pancreatitis, 10 during treatment with meglumine antimoniate, and 4 at the end of the treatment. Advanced LeishVet clinical stage was statistically associated with development of pancreatitis. In addition, nine dogs received prednisone at the beginning of treatment, but it was not statistically associated with the prevention of pancreatitis. Meglumine antimoniate remains the first line leishmanicidal treatment option for canine leishmaniosis, but it appears to induce pancreatitis in a significant percentage of dogs. Monitoring serum cPLI levels and performing an abdominal ultrasound should be considered when pancreatitis-associated clinical signs are observed, or when there is a high suspicion of circulating immune complexes in dogs with advanced LeishVet clinical stage.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Pancreas ; Leishmania ; Dog ; Antimonials
Publicado en:	Parasites & vectors, Vol. 17 (december 2024) , ISSN 1756-3305

DOI: 10.1186/s13071-024-06617-7
PMID: 39716313

18 p, 894.6 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados